An investigation by the group ‘Vaccines and dendritic cells‘of the Department of Biochemistry and Molecular Biology of the Complutense University of Madrid demonstrates for the first time that MV130 vaccine prevents the development of asthma Eosinophilic allergic in animal models, with a protective effect that is maintained up to nine weeks after the end of the treatment.
In this context, MV130, a pollivalent bacterial vaccine of sublingual administration developed by the Spanish company Immunotekhad already demonstrated efficacy in the Bronchiolitis reduction Children induced by virus. However, to date its role in the development and treatment of eosinophilic allergic asthma had not been studied.
The work, published in the magazine ‘Nature Communications’ and directed by the teacher Óscar Palomares, It has been carried out in collaboration with Dr. Laura Conejero and Dr. José Luis Subiza (Immunotek). These investigations are part of the Doctoral thesis of Ana Carmen Sevilla, Recently defended at the Complutense University of Madrid with outstanding Cum Laude qualification.
The results reveal that MV130 promotes innate immune responses and non -pathological adaptives against allergens of mite dust (HDM), responsible for the Eosinophilic asthma. This effect is produced by metabolic and transcriptomic reprogramming mechanisms of dendritic cells, key in the immune response. The study was carried out in Murid and Human preclinical models, using advanced techniques such as flow cytometry, histology, metabolic and transcriptomic studies, in vivid lung function analysis and transfer of dendritic cells.
Until now, it was known that MV130 reduced viral infections and bronchiolitis by trained innate immunity. This work demonstrates for the first time its protective effect sustained against asthma, positioning it as an ideal candidate for future clinical trials.
The results not only show the potential of MV130 in the prevention of asthma, but also provide key knowledge about the cellular and molecular mechanisms involved in the immune response against allergens. This Open the door to future clinical trials that validate their application in the prevention and treatment of eosinophilic allergic asthma.
These findings place MV130 as an innovative, safe and effective alternative for the prevention and treatment of asthma, and reinforce the potential of multipurpose bacterial vaccines administered by sublingual route as a therapeutic strategy of great relevance.
The research remains active within the public-private project CPP2023-010425 (UCM-INMUNOTEK, funded by the Ministry of Science, Innovation and Universities) and a new industrial doctorate recently granted by the Community of Madrid.
